Home › Compare › MDSQF vs ABBV
MDSQF yields 458.61% · ABBV yields 3.06%● Live data
📍 MDSQF pulled ahead of the other in Year 1
Combined, MDSQF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MDSQF + ABBV for your $10,000?
Minsud Resources Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Argentina. The company explores for copper, molybdenum, silver, and gold deposits. Its principal project is the Chita Valley project that consists of the Chita, Brechas Vacas, and Minas de Pinto mineral concessions, as well as five additional adjacent properties covering an area of approximately 19,883 hectares located in the province of San Juan, Argentina. The company also holds a 100% interest in La Rosita project, which consists of the Alfa II mine and Alfa III mining concessions covering an area of 5,986 hectares located in the low sulfidation epithermal metallogenic province of the Deseado Massif, Patagonia, Argentina. The company was formerly known as Rattlesnake Ventures Inc. and changed its name to Minsud Resources Corp. in May 2011. Minsud Resources Corp. was founded in 2003 and is headquartered in Toronto, Canada.
Full MDSQF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.